Antiviral activity of quercetin-3-β-O-D-glucoside against Zika virus infection.

Gary Wong, Shihua He, Vinayakumar Siragam, Yuhai Bi, Majambu Mbikay, Michel Chretien, Xiangguo Qiu
Author Information
  1. Gary Wong: Special Pathogens Program, Public Health Agency of Canada, Winnipeg, R3E 3R2, Canada.
  2. Shihua He: Special Pathogens Program, Public Health Agency of Canada, Winnipeg, R3E 3R2, Canada.
  3. Vinayakumar Siragam: Special Pathogens Program, Public Health Agency of Canada, Winnipeg, R3E 3R2, Canada.
  4. Yuhai Bi: Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, 511700, China.
  5. Majambu Mbikay: Functional Endoproteolysis Laboratory, Clinical Research Institute of Montreal, Montreal, H2W 1R7, Canada.
  6. Michel Chretien: Functional Endoproteolysis Laboratory, Clinical Research Institute of Montreal, Montreal, H2W 1R7, Canada.
  7. Xiangguo Qiu: Special Pathogens Program, Public Health Agency of Canada, Winnipeg, R3E 3R2, Canada. xiangguo.qiu@phac-aspc.gc.ca. ORCID

Abstract

Q3G is a natural derivative of quercetin and is already widely used in various foods and drinks. Our results clearly demonstrated that Q3G exerts antiviral activity against ZIKV in both tissue culture and knockout mice, and that post-exposure in vivo treatment with Q3G could have a beneficial effect. In the future, Q3G should be tested in human cell lines (such as Huh-7, HeLa, or K048, a fetal brain neural stem cell line) to provide further data supporting its potential efficacy in humans; in addition, live viral loads or viremia should be tested in treated animals to supplement the survival results observed in this study. Although the treatment regimens will need to be further optimized (i.e., dosage, frequency of treatment, and administration routes), our results support the results of Q3G efficacy studies in nonhuman primates against ZIKV infection. Further studies will also be needed to investigate the mechanism of Q3G antiviral action, in order to obtain valuable insights into the design of novel targets for antiviral therapeutics in the future.

References

  1. Food Chem Toxicol. 2007 Nov;45(11):2179-205 [PMID: 17698276]
  2. Molecules. 2011 Feb 28;16(3):2032-52 [PMID: 21358592]
  3. Biomed Pharmacother. 1997;51(8):305-10 [PMID: 9436520]
  4. Virol J. 2016 Jul 29;13:131 [PMID: 27473856]
  5. Cell. 2017 Mar 9;168(6):1114-1125.e10 [PMID: 28222903]
  6. Cell. 2016 Dec 1;167(6):1511-1524.e10 [PMID: 27884405]
  7. Cell Host Microbe. 2016 May 11;19(5):720-30 [PMID: 27066744]
  8. J Infect Dis. 2016 Nov 1;214(9):1357-1360 [PMID: 27521359]
  9. Emerg Infect Dis. 2008 Aug;14(8):1232-9 [PMID: 18680646]
  10. Clin Microbiol Rev. 2015 Jul;28(3):593-601 [PMID: 25972518]
  11. Mem Inst Oswaldo Cruz. 2015 Jun;110(4):569-72 [PMID: 26061233]
  12. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5182-8 [PMID: 27297486]
  13. Virol Sin. 2015 Aug;30(4):261-8 [PMID: 26268473]
  14. Nature. 2016 Dec 15;540(7633):438-442 [PMID: 27798603]
  15. Fitoterapia. 2015 Oct;106:256-71 [PMID: 26393898]

MeSH Term

Animals
Antiviral Agents
Chlorocebus aethiops
Disease Models, Animal
Mice, Knockout
Quercetin
Survival Analysis
Vero Cells
Viral Load
Virus Replication
Zika Virus
Zika Virus Infection

Chemicals

Antiviral Agents
isoquercitrin
Quercetin

Word Cloud

Created with Highcharts 10.0.0Q3GresultsantiviraltreatmentactivityZIKVfuturetestedcellefficacywillstudiesinfectionnaturalderivativequercetinalreadywidelyusedvariousfoodsdrinksclearlydemonstratedexertstissuecultureknockoutmicepost-exposurevivobeneficialeffecthumanlinesHuh-7HeLaK048fetalbrainneuralstemlineprovidedatasupportingpotentialhumansadditionliveviralloadsviremiatreatedanimalssupplementsurvivalobservedstudyAlthoughregimensneedoptimizediedosagefrequencyadministrationroutessupportnonhumanprimatesalsoneededinvestigatemechanismactionorderobtainvaluableinsightsdesignnoveltargetstherapeuticsAntiviralquercetin-3-β-O-D-glucosideZikavirus

Similar Articles

Cited By